AR070885A1 - Compuestos de azaindol para el tratamiento de trastornos del sistema nervioso central - Google Patents

Compuestos de azaindol para el tratamiento de trastornos del sistema nervioso central

Info

Publication number
AR070885A1
AR070885A1 ARP090100900A ARP090100900A AR070885A1 AR 070885 A1 AR070885 A1 AR 070885A1 AR P090100900 A ARP090100900 A AR P090100900A AR P090100900 A ARP090100900 A AR P090100900A AR 070885 A1 AR070885 A1 AR 070885A1
Authority
AR
Argentina
Prior art keywords
compounds
nervous system
central nervous
azaindol
treatment
Prior art date
Application number
ARP090100900A
Other languages
English (en)
Inventor
Timo Heinrich
Michael Katzer
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR070885A1 publication Critical patent/AR070885A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describe además un proceso para preparar estos compuestos, composiciones que los comprenden y un kit de unidades separadas y compuestos utiles para tratar desordenes del sistema nervioso central. Reivindicacion 1: Un compuesto que comprende una formula estructural general (1) en donde X es N o CH; Y es, cada uno en forma independiente, N o CH; W es (CH2)n, O, S o N; R1 es OH, OA, CN, halo, COR3, CH2R3, o SO2R3, R3 es OH, OA, NH2, NHA, o NA2; A es alquilo C1-6 que opcionalmente puede estar sustituido o sin sustituir; Z es un anillo de entre 3 y 12 miembros, saturado o insaturado, monocíclico o policíclico que opcionalmente tiene entre uno y cuatro átomos y que puede estar sustituido o sin sustituir; m es entre 2 y 6; n es entre 0 y 4; o una mezcla racémica, enantiomero, diasteroisomero, sal, solvato, hidrato o prodroga del mismo fisiologicamente aceptable.
ARP090100900A 2008-03-14 2009-03-13 Compuestos de azaindol para el tratamiento de trastornos del sistema nervioso central AR070885A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08004860 2008-03-14

Publications (1)

Publication Number Publication Date
AR070885A1 true AR070885A1 (es) 2010-05-12

Family

ID=40524561

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100900A AR070885A1 (es) 2008-03-14 2009-03-13 Compuestos de azaindol para el tratamiento de trastornos del sistema nervioso central

Country Status (14)

Country Link
US (1) US20110059982A1 (es)
EP (1) EP2250170A1 (es)
JP (1) JP2011517440A (es)
KR (1) KR20100134664A (es)
CN (1) CN101970436A (es)
AR (1) AR070885A1 (es)
AU (1) AU2009225025A1 (es)
BR (1) BRPI0909628A2 (es)
CA (1) CA2718138A1 (es)
EA (1) EA201001425A1 (es)
IL (1) IL207914A0 (es)
MX (1) MX2010009920A (es)
WO (1) WO2009112139A1 (es)
ZA (1) ZA201007325B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103420989B (zh) * 2012-05-15 2016-03-23 华中科技大学 苯并二噁烷类衍生物及其应用
EP3027607B1 (en) * 2013-07-29 2020-08-26 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use thereof
WO2015090235A1 (en) 2013-12-20 2015-06-25 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use thereof
CN106660489B (zh) * 2014-06-02 2019-07-09 上海延锋金桥汽车饰件系统有限公司 操纵台总成
WO2016192657A1 (en) 2015-06-03 2016-12-08 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use and use thereof
JP6657974B2 (ja) * 2016-01-12 2020-03-04 トヨタ紡織株式会社 金属樹脂一体成形品及びその製造方法
CN107459510B (zh) * 2016-06-06 2021-06-25 华东师范大学 异恶唑类化合物及其应用
JP7282082B2 (ja) * 2017-09-29 2023-05-26 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換ピリミジンピペラジン化合物及びその使用
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
US20230059009A1 (en) * 2019-12-18 2023-02-23 The Regents Of The University Of California Inhibitors of lin28 and methods of use thereof
KR102347368B1 (ko) * 2020-11-03 2022-01-07 (주)케이메디켐 신규한 아자인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물
WO2024148274A1 (en) * 2023-01-05 2024-07-11 Apellis Pharmaceuticals, Inc. Complement inhibition
CN120817935A (zh) * 2024-04-15 2025-10-21 复旦大学附属肿瘤医院 一种杂(芳)环取代环状二胺类化合物及其在制备治疗和/或预防肿瘤药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US4954502A (en) * 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
CA2043709C (en) * 1990-06-29 2002-01-22 David W. Smith Antimigraine alkoxypyrimidine derivatives
JP2003521443A (ja) * 1998-06-19 2003-07-15 ハー・ルンドベック・アクチエゼルスカベット ４，５，６及び７−インドール及びインドリン誘導体、その製造方法及びその使用方法
US6258819B1 (en) * 1999-08-05 2001-07-10 Syntex (U.S.A.) Llc Substituted 2(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)-4(3H)-azaquinazolinones
BR0016952A (pt) * 1999-12-30 2002-10-08 Lundbeck & Co As H Compostos derivados de fenil-piperazina substituìdos, composição farmacêutica, uso e método
DE10112151A1 (de) * 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide

Also Published As

Publication number Publication date
BRPI0909628A2 (pt) 2015-09-22
CA2718138A1 (en) 2009-09-17
CN101970436A (zh) 2011-02-09
EA201001425A1 (ru) 2011-06-30
AU2009225025A1 (en) 2009-09-17
KR20100134664A (ko) 2010-12-23
US20110059982A1 (en) 2011-03-10
EP2250170A1 (en) 2010-11-17
MX2010009920A (es) 2010-09-30
IL207914A0 (en) 2010-12-30
ZA201007325B (en) 2011-06-29
WO2009112139A1 (en) 2009-09-17
JP2011517440A (ja) 2011-06-09

Similar Documents

Publication Publication Date Title
CL2018000036A1 (es) Derivados etinilo
PE20251288A1 (es) Compuestos heterociclicos como inmunomoduladores
AR068051A1 (es) Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer.
AR068510A1 (es) Derivados de 4-fenil-1h-piridin-2-ona - 1,3 disustituidos, composiciones farmaceuticas que los contienen y usos de los mismos para tratar o prevenir trastornos del sistema nervioso central.
AR081627A1 (es) Compuestos heterociclicos de nitrogeno insaturados utiles como inhibidores de pde10
CL2011003302A1 (es) Compuestos derivados de amida del acido alquil-sulfonico; composicion farmaceutica; uso de los compuestos como moduladores de la disfuncion de glutamato para prevenir o tratar trastornos neurologicos y psiquiatricos como esquizofrenia, enfermedad de alzheimer, trastornos de deficit de atencion/hiperactividad, perdida de audicion, entre otros.
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
UY28374A1 (es) Agentes terapéuticos
AR085004A1 (es) Inhibidores selectivos de glicosidasas y usos de los mismos
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
UY26020A1 (es) Inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc.
AR053120A1 (es) Aminopiridinas como inhibidores de beta secretasa
AR078756A1 (es) Moduladores alostericos positivos (map)
CO2019011604A2 (es) Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos
EA201492170A1 (ru) Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ
PE20200341A1 (es) Composiciones y compuestos terapeuticos y metodos para utilizarlos
AR058151A1 (es) Compuestos antagosnistas de los receptores 2 de dopamina de rapida disociacion
CR10866A (es) Derivados de aril sulfamida y metodos para su uso
MX2020001157A (es) Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc).
AR104331A1 (es) Derivados de tetrazol
PE20190964A1 (es) Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica
AR074467A1 (es) Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras.
AR105662A1 (es) Derivados de piridina y de pirimidina como inhibidores del eaat3
AR072880A1 (es) Derivados nitrogenados de la pancratistatina
ES2676198T3 (es) Derivados amino-quinoxalina para el tratamiento de enfermedades neurodegenerativas

Legal Events

Date Code Title Description
FB Suspension of granting procedure